Citadel Advisors
ORKA

Citadel Advisors’s Oruka Therapeutics ORKA Stock Holding History

Citadel Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27M Buy
23,900
+12,900
+117% +$860K ﹤0.01% 6274
2026
Q1 		$540K Buy
+11,000
New +$382K ﹤0.01% 9114
2025
Q4 		– Sell
-12,500
Closed -$240K – 14421
2025
Q3 		$240K Buy
+12,500
New +$185K ﹤0.01% 10852
2024
Q3 		– Sell
-1,842
Closed -$84.6K – 15459
2024
Q2 		$84.6K Sell
1,842
-2,716
-60% -$108K ﹤0.01% 11142
2024
Q1 		$97.4K Buy
4,558
+4,066
+826% +$80.9K ﹤0.01% 11394
2023
Q4 		$10K Sell
492
-400
-45% -$8.98K ﹤0.01% 13124
2023
Q3 		$21.5K Sell
892
-283
-24% -$6.93K ﹤0.01% 12571
2023
Q2 		$28.6K Buy
1,175
+450
+62% +$11.1K ﹤0.01% 12402
2023
Q1 		$17.3K Sell
725
-308
-30% -$8.12K ﹤0.01% 13164
2022
Q4 		$29.3K Buy
+1,033
New +$26.5K ﹤0.01% 12777
2022
Q2 		– Sell
-3,067
Closed -$85K – 14302
2022
Q1 		$85K Buy
3,067
+667
+28% +$16.5K ﹤0.01% 12428
2021
Q4 		$62K Buy
+2,400
New +$72.3K ﹤0.01% 13123
2021
Q2 		– Sell
-3,450
Closed -$151K – 14576
2021
Q1 		$151K Buy
+3,450
New +$181K ﹤0.01% 12026

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citadel Advisors's ORKA Position: Q2 2026 in Review

Citadel Advisors increased its Oruka Therapeutics (ORKA) stake by 11% in Q2 2026, buying an estimated $7.43M and bringing the position to 1,119,011 shares worth $106M. The position accounts for 0.01% of the portfolio, ranked #930.

Citadel Advisors first reported a position in ORKA in Q2 2014 and has held it in 25 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Citadel Advisors held 1,119,011 shares of Oruka Therapeutics worth $106M as of Q2 2026.
  • Citadel Advisors bought 111,474 Oruka Therapeutics shares in Q2 2026, an estimated $7.43M.
  • Oruka Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #930 holding.
  • Citadel Advisors first reported a position in Oruka Therapeutics in Q2 2014 and has held it in 25 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.